

# *Genetics*

---

---

## NEWS

OF THE NATIONAL ACADEMY OF SCIENCES OF THE REPUBLIC OF KAZAKHSTAN

SERIES OF BIOLOGICAL AND MEDICAL

ISSN 2224-5308

Volume 3, Number 339 (2020), 5 – 13

<https://doi.org/10.32014/2020.2519-1629.17>

UDC 577.218

IRSTI 34.15.25

**D.D. Mukushkina<sup>1</sup>, S. Labeit<sup>2</sup>, A.T. Ivashchenko<sup>1</sup>**

<sup>1</sup>Al-Farabi Kazakh National University,

Scientific research institute of biology and biotechnology problems, Almaty, Kazakhstan;

<sup>2</sup>Institute for Integrative Pathophysiology of Heidelberg University, Mannheim, Germany.

E-mail: dina.mukushkina@gmail.com, labeit@medma.de, [a.ivashchenko@gmail.com](mailto:a.ivashchenko@gmail.com)

## **ASSOCIATIONS OF miRNA WITH mRNA OF ATHEROSCLEROSIS CANDIDATE GENES**

**Abstract.** Atherosclerosis is a complex multifactorial disease where multiple genetic and environmental factors are involved. This research presents the characteristics of miRNA (mRNA-inhibiting RNA) interactions with mRNA of atherosclerosis candidate genes. 46, 59, and 33 target genes were identified with miRNA binding sites in the 5'-untranslated region (5'UTR), CDS (coding sequence), and 3'-untranslated region (3'UTR), respectively. Genes have been identified which are most susceptible to miRNA because of interaction with miRNA in more than one mRNA region: *ABCA1*; *ABCG8*; *ADCY9*; *ADRB3*; *APH1B*; *ALOX15*; *HMOX1*; *GAS6*; *GNB3*; *ID3*; *LRP6*; *PDE4D*; *PHACTR1*; *PROC RTN3*; *SERPINE1*; *TIMP3*; *TNFSF12* and *ZNF202*. Based on the criteria selected in our research, candidate genes were determined that have a free energy interaction with miRNAs equal to -120 kJ/mole and higher in the following associations: in 5'UTR - ID01336.3p-miR and *ADCY9*, ID02142.3p-miR and *ALDH2*, miR-4707-5p and *APH1B*, ID00216.3p-miR and *LGALS2*, ID02363.5p-miR and *NOS3*, ID00551.3p-miR and *NPCI1*, ID01310.3p-miR and *PDE4D*, ID03397.3p-miR and *RTN4*, ID00561.3p-miR and *SERPINE1*, ID02903.3p-miR and *TIMP3*, ID01323.3p-miR and *TNFRSF11B*, ID01770 .3p-miR and *ZNF202*; in CDS region - ID03064.3p-miR and *ABCG8*; ID02771.3p-miR and *ADIPOR1*; ID00252.5p-miR and *ANGPTL2*; ID00457.3p-miR and *APOA1*; ID01641.3p-miR and *PDE4D*; ID02050.3p-miR and *TNF*; ID01804.3p-miR and *XBPI*; ID00182.5p-miR and *ZNF202*; in 3'UTR - ID00305.3p-miR and *ADRB3*; ID01213.5p-miR and *AGTR2*; ID02221.3p-miR and *CDK5*; ID03371.3p-miR and *ID3*; ID02229.3p-miR and *LCN2*; ID00704.5p-miR and *TLR9*. Identified associations could be used as biomarkers in diagnosis of atherosclerosis.

**Key words:** atherosclerosis, miRNA, mRNA, candidate genes, associations.

**Introduction.** The diagnosis, prevention and treatment of atherosclerosis are still the most important tasks of modern medicine. And accordingly, the success of treatment of diseases such as heart attack, stroke and other cardiovascular complications largely depends on the solution of such a problem like atherosclerosis [1]. According to statistical calculations, the share of deaths from cardiovascular diseases in the world, among which atherosclerosis is one of the first, continues to increase and in 2020 year could reach to 31.5% [2].

Despite the fact that modern clinical medicine is focused primarily on the use of drugs, non-pharmacological treatment methods attract specialists in the field of prevention and treatment. A growing number of studies have emphasized the importance of miRNAs (mRNA-inhibiting RNA) in the development of atherosclerosis. MiRNAs have been shown to be involved in the development of atherosclerosis by regulating the expression of atherosclerosis candidate genes [3].

The miRNAs are nanoscale RNAs which ranging in length from 18 to 27 nucleotides [4], capable of regulating the expression of more than 60% of all protein coding genes [5, 6, 7]. The miRNAs are able to regulate gene expression at the translation by binding to mRNA of the target gene. With complete complementarity of miRNA and mRNA, the latter either degrade or block the activity of the gene. However, incompleteness is most often observed, in which case miRNAs inhibit translation by binding to the 5'-untranslated region (5'UTR), 3'-untranslated region (3'UTR) or protein coding sequence (CDS) of mRNA [8,9,10]. The miRNAs are involved in many biological processes at the stages of development of atherosclerosis, from early endothelial dysfunction to rupture of an unstable atherosclerotic plaque [11]. The determination of miRNAs in the blood of patients could be a direction for the diagnosis of such clinical complications of atherosclerosis as ischemic stroke and myocardial infarction [8,11]. Several thousand publications describe changes in miRNAs concentrations in various diseases and changes in the expression of protein coding genes. In such experiments, correlations are usually established between changes in expression from one to tens of miRNAs and supposed target genes. In this situation, the question arises of the significance of such experiments in establishing the existing direct interactions of miRNAs and candidate genes. As a result, there are not methods for diagnosing diseases using miRNAs and are not therapeutic methods for treating diseases involving these molecules. There are many reasons for this outcome, and some of them are given below. Currently, more than seven thousand miRNAs are known that can regulate the expression of about 20 thousand human genes with varying efficiencies. When setting the task of studying the effect of miRNAs on genes using bioinformatics methods, it is possible to establish the most effective associations of miRNAs and target genes. However, existing programs for searching for miRNAs binding sites with mRNAs analyze only sequences of 6-8 nucleotides in length at the 5'UTR of miRNA. As a result, programs predict many false positive binding sites. This misconception is the main reason for the failure to identify miRNAs associations and target genes. An approach is needed to evaluate the comparative participation of all miRNAs with all genes and to determine the quantitative characteristics of miRNAs interactions with mRNAs. In addition, it is necessary to establish the estimated concentrations of miRNAs and mRNAs of target genes, because the result of miRNAs interactions with mRNAs will depend on their ratio. Further researches are needed to fully understand the role of miRNAs in atherosclerosis pathogenesis and in the development of its complications, as well as in the development of targeted therapeutic approaches.

**Materials and methods.** The nucleotide sequences of mRNA candidate genes were obtained from GenBank (<http://www.ncbi.nlm.nih.gov>). The miRNA base consisted of 2565 miRNAs that were downloaded from miRBase (<http://mirbase.org>) and 3707 miRNAs were obtained from a report by London E. *et al.* [12]. A search for the target genes of miRNAs was performed using the MirTarget program [13]. This program defines the following binding characteristics: the start of the miRNA binding site of mRNA; the locations of miRNA binding sites in 5'UTR, CDS and 3'UTR regions; the interaction free energy ( $\Delta G$ , kJ/mole). For each binding site, the ratio  $\Delta G/\Delta G_m$  (%) was determined, where  $\Delta G_m$  is equal to the free energy binding of miRNA with its full complementary nucleotide sequence. The obtained miRNA-mRNA binding sites were selected with the  $\Delta G/\Delta G_m$  ratio of 90% or more.

**Results and discussion.** The search for miRNA binding sites was carried out in the 5'UTR, CDS and 3'UTR mRNA of the candidate atherosclerosis genes in order to reveal interaction features of miRNAs in these regions. To option the most effective associations of miRNA and candidate genes, the following criteria and characteristics of the miRNAs interaction with mRNAs of target genes were selected: the value of the interaction free energy of miRNAs with mRNAs of the candidate target gene; the degree of complementarity of miRNA nucleotides and binding sites of mRNA candidate genes; the possibility of the candidate gene participation on the basis of its function in studied disease. There are others, depending on the characteristics of the disease in addition to these criteria and characteristics. Priority between criteria and characteristics is difficult to establish in advance, so there will always be uncertainty in the correct choice of their list. This difficulty is due to various causes of the disease at an early stage and deviations from the norm in subsequent stages. The most effective associations of miRNA and atherosclerosis candidate genes were selected which based on the above considerations.

Table 1 presents the characteristics of miRNAs interactions with mRNAs of 47 candidate atherosclerosis genes. Free energy interaction ( $\Delta G$ ) of miRNAs with mRNA is -120 kJ/mole or more could be recommended as associations: ID01336.3p-miR and *ADCY9*, ID02142.3p-miR and *ALDH2*,

miR-4707-5p and *APH1B*, ID00216.3p-miR and *CD40*, miR-6789-5p and *HIF1A*, ID01242.3p-miR and *LGALS2*, ID02363.5p-miR and *NOS3*, ID00551.3p-miR and *NPC1*, ID01310.3p-miR and *PDE4D*, ID03397.3p-miR and *PTGS2*, ID00561.3p-miR and *RTP4*, ID01098.3p-miR and *SERPINE1*, ID02903.3p-miR and *TIMP3*, ID01323.3p-miR and *TNFRSF11B*, ID01770.3p-miR and *ZNF202*. Three associations of miRNA and candidate genes (ID02813.3p-miR and *CAPN10*, ID01152.3p-miR and *HMOX1*, ID01840.5p-miR and *PHACTR1*) were characterized by the value of  $\Delta G/\Delta G_m$  equal to 95%, which indicates an almost complete complementarity of the interaction of miRNA nucleotides and binding site nucleotides.

Table 1 - Characteristics of miRNA interactions  
in the 5'UTR of the mRNAs of atherosclerosis candidate genes

| Gene             | miRNA          | Start of site, nt | $\Delta G$ , kJ/mole | $\Delta G/\Delta G_m$ , % | Length, nt |
|------------------|----------------|-------------------|----------------------|---------------------------|------------|
| <i>ABCA1</i>     | miR-4435       | 331               | -110                 | 91                        | 22         |
| <i>ABCG8</i>     | ID00122.5p-miR | 55                | -110                 | 90                        | 22         |
| <i>ADCY9</i>     | ID01336.3p-miR | 465               | -136                 | 89                        | 24         |
| <i>ADRB3</i>     | ID01568.3p-miR | 36                | -115                 | 90                        | 22         |
| <i>AGT</i>       | miR-3126-5p    | 326               | -108                 | 91                        | 22         |
| <i>ALDH2</i>     | ID02142.3p-miR | 8                 | -123                 | 92                        | 21         |
| <i>APH1B</i>     | miR-4707-5p    | 5                 | -129                 | 92                        | 23         |
| <i>CAPN10</i>    | ID02813.3p-miR | 105               | -115                 | 95                        | 20         |
| <i>CD40</i>      | ID00216.3p-miR | 10                | -123                 | 91                        | 23         |
| <i>CX3CRI</i>    | ID01330.3p-miR | 164               | -119                 | 89                        | 23         |
| <i>DPP4</i>      | ID02385.3p-miR | 369               | -108                 | 93                        | 20         |
| <i>FGF23</i>     | miR-6878-3p    | 48                | -102                 | 91                        | 21         |
| <i>GAS6</i>      | miR-4749-5p    | 320               | -117                 | 92                        | 22         |
| <i>GNB3</i>      | ID00388.3p-miR | 234               | -110                 | 87                        | 22         |
| <i>HBEGF</i>     | ID03416.5p-miR | 66                | -117                 | 92                        | 20         |
| <i>HIF1A</i>     | miR-6789-5p    | 53                | -132                 | 90                        | 24         |
| <i>HMOX1</i>     | ID01152.3p-miR | 75                | -113                 | 95                        | 20         |
| <i>ICAMI</i>     | ID00195.3p-miR | 106               | -117                 | 89                        | 23         |
| <i>ID3</i>       | ID00461.3p-miR | 238               | -113                 | 90                        | 22         |
| <i>IL15</i>      | ID01713.5p-miR | 63                | -115                 | 92                        | 20         |
| <i>IL18</i>      | miR-548au-3p   | 102               | -100                 | 90                        | 21         |
| <i>IRS2</i>      | ID02344.3p-miR | 66                | -132                 | 91                        | 24         |
| <i>KDR</i>       | ID02534.5p-miR | 143               | -119                 | 92                        | 22         |
| <i>LGALS2</i>    | ID01242.3p-miR | 75                | -123                 | 89                        | 24         |
| <i>LPL</i>       | miR-4430       | 287               | -96                  | 94                        | 18         |
| <i>LRP6</i>      | miR-6752-5p    | 68                | -119                 | 90                        | 22         |
| <i>MMP2</i>      | ID02014.5p-miR | 264               | -117                 | 89                        | 23         |
| <i>NOS3</i>      | ID02363.5p-miR | 200               | -123                 | 88                        | 24         |
| <i>NPC1</i>      | ID00551.3p-miR | 34                | -121                 | 88                        | 24         |
| <i>NR4A1</i>     | ID01213.5p-miR | 139               | -119                 | 89                        | 23         |
| <i>PDE4D</i>     | ID01310.3p-miR | 66                | -121                 | 92                        | 22         |
| <i>PHACTR1</i>   | ID01840.5p-miR | 96                | -113                 | 95                        | 22         |
| <i>PLA2G7</i>    | miR-4722-5p    | 40                | -119                 | 90                        | 23         |
| <i>PLTP</i>      | ID01382.3p-miR | 108               | -113                 | 93                        | 20         |
| <i>PON2</i>      | ID02200.3p-miR | 8                 | -119                 | 90                        | 22         |
| <i>PTGS2</i>     | ID03397.3p-miR | 108               | -123                 | 92                        | 21         |
| <i>PTX3</i>      | miR-6866-5p    | 36                | -106                 | 91                        | 23         |
| <i>RTN4</i>      | ID00561.3p-miR | 247               | -121                 | 93                        | 21         |
| <i>SCAP</i>      | ID00757.3p-miR | 23                | -108                 | 91                        | 21         |
| <i>SELP</i>      | ID03109.5p-miR | 49                | -106                 | 94                        | 21         |
| <i>SERPINE1</i>  | ID01098.3p-miR | 30                | -123                 | 88                        | 24         |
| <i>SOAT1</i>     | ID03036.3p-miR | 46                | -115                 | 89                        | 23         |
| <i>SPPI</i>      | miR-1913       | 60                | -117                 | 92                        | 22         |
| <i>TIMP3</i>     | ID02903.3p-miR | 1102              | -121                 | 90                        | 22         |
| <i>TNFRSF11B</i> | ID01323.3p-miR | 115               | -125                 | 92                        | 22         |
| <i>TNFSF12</i>   | ID01254.5p-miR | 56                | -110                 | 91                        | 21         |
| <i>ZNF202</i>    | ID01770.3p-miR | 70                | -123                 | 94                        | 22         |

The results of the analysis of miRNAs interactions in the CDS region of 59 candidate genes are given in table 2. Among them, associations can be distinguished with a free energy ( $\Delta G$ ) is -120 kJ/mole and higher: ID03064.3p-miR and *ABCG8*; ID02771.3p-miR and *ADIPOR1*; ID00252.5p-miR and *ANGPTL2*; ID00457.3p-miR and *APOA1*; ID01641.3p-miR and *PDE4D*; ID02050.3p-miR and *TNF*; ID01804.3p-miR and *XBP1*; ID00182.5p-miR and *ZNF202*. Four associations of miRNAs and candidate genes were also identified, which were characterized by a  $\Delta G/\Delta G_m$  value of 95% or more: ID02129.5p-miR and *CD4*; ID01797.3p-miR and *PLA2G10*; miR-1281 and *PHACTR1*; ID00182.5p-miR and *ZNF202*.

Table 2 - Characteristics of miRNA interactions in the CDS of the mRNAs of atherosclerosis candidate genes

| Gene            | miRNA          | Start of site, nt | $\Delta G$ , kJ/mole | $\Delta G/\Delta G_m$ , % | Length, nt |
|-----------------|----------------|-------------------|----------------------|---------------------------|------------|
| 1               | 2              | 3                 | 4                    | 5                         | 6          |
| <i>ABCA1</i>    | ID00653.3p-miR | 6416              | -110                 | 90                        | 23         |
| <i>ABCG5</i>    | ID03409.5p-miR | 441               | -115                 | 93                        | 20         |
| <i>ABCG8</i>    | ID03064.3p-miR | 1727              | -136                 | 89                        | 24         |
| <i>ADCY9</i>    | ID01569.3p-miR | 2981              | -115                 | 92                        | 20         |
| <i>ADIPOR1</i>  | ID02771.3p-miR | 1092              | -121                 | 93                        | 22         |
| <i>AGTR1</i>    | ID02795.5p-miR | 102               | -117                 | 92                        | 22         |
| <i>AHSG</i>     | miR-6794-5p    | 955               | -108                 | 93                        | 20         |
| <i>ALOX15</i>   | ID01385.5p-miR | 258               | -110                 | 91                        | 21         |
| <i>ANGPTL2</i>  | ID00252.5p-miR | 1145              | -136                 | 91                        | 24         |
| <i>ANXA5</i>    | miR-3613-5p    | 475               | -96                  | 92                        | 22         |
| <i>APOA1</i>    | ID00457.3p-miR | 841               | -123                 | 91                        | 22         |
| <i>APOL1</i>    | miR-146b-3p    | 1506              | -113                 | 93                        | 22         |
| <i>BRAP</i>     | miR-1908-5p    | 233               | -113                 | 91                        | 21         |
| <i>CD4</i>      | ID02129.5p-miR | 1090              | -113                 | 95                        | 20         |
| <i>CDKN1C</i>   | ID01313.3p-miR | 360               | -110                 | 91                        | 21         |
| <i>COMT</i>     | ID00215.3p-miR | 199               | -108                 | 91                        | 21         |
| <i>CPE</i>      | ID02448.5p-miR | 355               | -115                 | 90                        | 22         |
| <i>CX3CL1</i>   | ID02488.5p-miR | 561               | -113                 | 93                        | 21         |
| <i>CXCR3</i>    | ID00240.5p-miR | 293               | -106                 | 91                        | 21         |
| <i>CXCR4</i>    | miR-3119       | 736               | -93                  | 92                        | 20         |
| <i>CYBA</i>     | ID01251.3p-miR | 578               | -119                 | 92                        | 22         |
| <i>CYP27A1</i>  | ID01201.5p-miR | 557               | -106                 | 91                        | 21         |
| <i>CYP2E1</i>   | miR-4445-3p    | 1366              | -100                 | 92                        | 21         |
| <i>FADS2</i>    | ID01205.5p-miR | 1447              | -110                 | 90                        | 22         |
| <i>GAS6</i>     | ID01154.5p-miR | 2163              | -115                 | 93                        | 20         |
| <i>GNB3</i>     | miR-6736-3     | 1167              | -104                 | 91                        | 21         |
| <i>GSTM1</i>    | ID01955.3p-miR | 462               | -108                 | 89                        | 23         |
| <i>HP</i>       | ID00253.5p-miR | 1178              | -98                  | 92                        | 20         |
| <i>LPCAT3</i>   | ID02232.3p-miR | 740               | -110                 | 90                        | 22         |
| <i>LRP6</i>     | ID03063.3p-miR | 3421              | -110                 | 90                        | 22         |
| <i>LTA</i>      | miR-6831-5p    | 581               | -117                 | 90                        | 24         |
| <i>MMP3</i>     | ID00314.3p-miR | 132               | -119                 | 93                        | 23         |
| <i>NLRP3</i>    | ID00662.3p-miR | 3638              | -102                 | 92                        | 20         |
| <i>NPC1</i>     | miR-4459       | 1031              | -119                 | 93                        | 22         |
| <i>PCSK9</i>    | ID01810.3p-miR | 1052              | -115                 | 89                        | 23         |
| <i>PDE4D</i>    | ID01641.3p-miR | 335               | -132                 | 89                        | 24         |
| <i>PHACTR1</i>  | miR-1281       | 1563              | -93                  | 96                        | 17         |
| <i>PIN1</i>     | ID02643.3p-miR | 627               | -119                 | 89                        | 23         |
| <i>PLA2G10</i>  | ID01797.3p-miR | 731               | -110                 | 95                        | 20         |
| <i>PNPLA3</i>   | ID02224.3p-miR | 918               | -106                 | 93                        | 22         |
| <i>PON1</i>     | miR-5003-3p    | 330               | -100                 | 92                        | 21         |
| <i>PROC</i>     | miR-185-3p     | 744               | -110                 | 90                        | 22         |
| <i>RTN3</i>     | miR-718        | 254               | -117                 | 92                        | 21         |
| <i>SELE</i>     | ID03022.3p-miR | 829               | -100                 | 90                        | 22         |
| <i>SERPINE1</i> | miR-4758-3p    | 276               | -119                 | 90                        | 23         |
| <i>SHBG</i>     | miR-6746-5p    | 821               | -115                 | 90                        | 22         |
| <i>SOCS1</i>    | ID00171.3p-miR | 461               | -115                 | 92                        | 20         |
| <i>TGFB1</i>    | miR-6742-5p    | 2046              | -110                 | 90                        | 22         |
| <i>THBS2</i>    | miR-598-3p     | 2941              | -104                 | 91                        | 22         |

| Continuation of table 2 |                |     |      |    |    |
|-------------------------|----------------|-----|------|----|----|
| 1                       | 2              | 3   | 4    | 5  | 6  |
| <i>TLR2</i>             | ID00935.5p-miR | 295 | -104 | 94 | 20 |
| <i>TNF</i>              | ID02050.3p-miR | 230 | -121 | 92 | 23 |
| <i>TNFSF12</i>          | miR-6739-3p    | 491 | -100 | 92 | 21 |
| <i>TNNT2</i>            | ID02813.3p-miR | 164 | -113 | 93 | 20 |
| <i>TRIB3</i>            | miR-596        | 731 | -113 | 91 | 21 |
| <i>TSPO</i>             | ID02332.3p-miR | 134 | -115 | 89 | 23 |
| <i>UCP2</i>             | miR-6878-3p    | 509 | -102 | 91 | 21 |
| <i>XBP1</i>             | ID01804.3p-miR | 110 | -134 | 91 | 23 |
| <i>ZNF202</i>           | ID00182.5p-miR | 935 | -125 | 97 | 23 |

Data of the miRNAs interactions with mRNA of 33 candidate genes in 3'UTR region are shown in table 3. Based on these interactions, six associations can be distinguished, which were characterized by free energy equal to ( $\Delta G$ ) -120 kJ/mole and higher: ID00305.3p-miR and *ADRB3*; ID01213.5p-miR and *AGTR2*; ID02221.3p-miR and *CDK5*; ID03371.3p-miR and *ID3*; ID02229.3p-miR and *LCN2*; ID00704.5p-miR and *TLR9*. Of all the revealed interactions in the 3'UTRs, one maximum index of complementarity equal to 98% was determined between miR-1273g-3p and mRNA of *ALOX15* gene.

Table 3 - Characteristics of miRNA interactions  
in the 3'UTR of the mRNAs of atherosclerosis candidate genes

| Gene           | miRNA          | Start of site, nt | $\Delta G$ , kJ/mole | $\Delta G/\Delta G_m$ , % | Length, nt |
|----------------|----------------|-------------------|----------------------|---------------------------|------------|
| <i>ADCY9</i>   | miR-2392       | 5360              | -102                 | 92                        | 20         |
| <i>ADIPO2</i>  | ID01700.3p-miR | 1398              | -119                 | 90                        | 23         |
| <i>ADRB3</i>   | ID00305.3p-miR | 2347              | -121                 | 88                        | 24         |
| <i>AGTR2</i>   | ID01213.5p-miR | 2307              | -121                 | 90                        | 23         |
| <i>ALOX15</i>  | miR-1273g-3p   | 2393              | -115                 | 98                        | 21         |
| <i>APLN</i>    | miR-3661       | 1260              | -110                 | 90                        | 22         |
| <i>APH1B</i>   | ID01642.3p-miR | 2230              | -119                 | 90                        | 24         |
| <i>CDK5</i>    | ID02221.3p-miR | 1096              | -125                 | 89                        | 24         |
| <i>CHI3L1</i>  | ID01707.5p-miR | 1497              | -110                 | 93                        | 22         |
| <i>CXCL12</i>  | ID00483.3p-miR | 932               | -119                 | 90                        | 23         |
| <i>CXCL13</i>  | miR-4326       | 830               | -100                 | 92                        | 20         |
| <i>CXCL5</i>   | miR-567        | 1817              | -108                 | 91                        | 23         |
| <i>CYP27A1</i> | ID00964.5p-miR | 2078              | -119                 | 90                        | 24         |
| <i>DAP</i>     | miR-6762-5p    | 525               | -119                 | 90                        | 23         |
| <i>DKK1</i>    | ID00436.3p-miR | 1580              | -106                 | 91                        | 23         |
| <i>FASLG</i>   | ID00790.3p-miR | 1595              | -104                 | 89                        | 23         |
| <i>HMOX1</i>   | miR-3155a      | 1227              | -106                 | 91                        | 21         |
| <i>ID3</i>     | ID03371.3p-miR | 974               | -123                 | 91                        | 23         |
| <i>IL10</i>    | ID01332.3p-miR | 1200              | -110                 | 90                        | 22         |
| <i>LCN2</i>    | ID02229.3p-miR | 682               | -123                 | 94                        | 21         |
| <i>LRP6</i>    | miR-4693-3p    | 9159              | -108                 | 94                        | 23         |
| <i>NCEH1</i>   | miR-6728-3p    | 3101              | -106                 | 91                        | 21         |
| <i>PCSK9</i>   | miR-6877-3p    | 2468              | -110                 | 91                        | 21         |
| <i>PDE4D</i>   | ID02141.5p-miR | 7731              | -100                 | 90                        | 22         |
| <i>PROC</i>    | miR-6736-3p    | 1672              | -106                 | 93                        | 21         |
| <i>PSMA6</i>   | ID02529.5p-miR | 954               | -106                 | 93                        | 20         |
| <i>ROCK1</i>   | miR-5010-3p    | 5650              | -106                 | 91                        | 22         |
| <i>RTN3</i>    | miR-6785-5p    | 4652              | -110                 | 90                        | 22         |
| <i>S100A9</i>  | ID02629.5p-miR | 436               | -108                 | 93                        | 21         |
| <i>SELPLG</i>  | ID02248.5p-miR | 1818              | -106                 | 94                        | 20         |
| <i>TIMP3</i>   | miR-1224-5p    | 3267              | -104                 | 96                        | 19         |
| <i>TLR9</i>    | ID00704.5p-miR | 3779              | -123                 | 88                        | 24         |
| <i>TNFSF12</i> | miR-3151-5p    | 907               | -108                 | 93                        | 21         |

From the above Tables it follows that in the protein coding region, more than all single interactions of different miRNAs with mRNAs were determined in comparison with the 3'UTR and 5'UTR regions. In the course of studying the miRNAs interactions with mRNAs various regions of the atherosclerosis candidate genes, there were identified that single associations not only in one mRNA region. Candidate genes which had interactions with miRNAs in two regions: *ABCA1; ABCG8; ADRB3; APH1B; ALOX15; HMOX1; GAS6; GNB3; ID3; PHACTR1; PROC RTN3; SERPINE1; TIMP3* and *ZNF202*, and in three regions: *ADCY9; LRP6; PDE4D* and *TNFSF12*. Accordingly, these genes are most affected by different miRNAs.

Genes selected in associations, including which have significant interactions with miRNAs with high free energy, are directly involved in the development of atherosclerosis. For example, disorders of lipid metabolism often accompany the development of cardiovascular pathology. Polymorphisms of genes involved in the control of lipid metabolism have been identified. These are the genes of apolipoproteins A (LPA), B (APOB), C (APOC1-3), E (APOE), low density lipoprotein receptor (LPLR), paraoxonase (PON1), etc. [14]. An inverse relationship has been established between high density lipoproteins (HDL) and atherosclerosis. Lecithin-cholesterol-acyltransferase (LCAT) is a key enzyme in cholesterol reverse transport and HDL metabolism. Mutations in *LCAT* gene are associated with low HDL and an increased risk of dyslipidemia and atherosclerosis [15]. Also, the *LRP* gene is a multifunctional receptor that is involved in several biological processes associated with the development of atherosclerosis [16]. The absorption of exogenous cholesterol occurs in enterocytes using a special NPC1 transport system. Mutations in the *NPC1* gene contribute to the accumulation of huge amounts of cholesterol due to impaired intracellular transport of lipids, which leads to the development of atherosclerosis [17]. It was found that the level and activity of the *CETP* gene is associated with the level of HDL in plasma, which affects the risk of developing atherosclerosis [18]. Endothelial dysfunction plays a key role in the development and progression of this disease. The reduced bioavailability of nitric oxide (NO) obtained by endothelial NO synthase (eNOS) leads to deterioration in endothelial relaxation of the arteries. eNOS is encoded by the *NOS3* gene, the polymorphisms of which are associated with atherosclerosis [19]. Genes, which connected with inflammation, are also associated with the development of this disease. It has been suggested that toll-like receptors (TLRs) may be a key link between the development of cardiovascular disease and the immune system. TLR expression is regulated in endothelial cells and macrophages of atherosclerotic lesions. A299G polymorphism of *TLR* gene is associated with a risk of carotid arteriosclerosis, acute coronary syndrome [20]. Polymorphisms of *LGALS2* gene of galectin-2 protein were also identified as a genetic risk factor for myocardial infarction and coronary atherosclerosis [21].

**Conclusion.** The associations of a large number of genes with atherosclerosis reflect the enormous complexity of this disease. Therefore, it is important to establish associations of these genes with miRNAs. The data obtained in this research significantly expand the understanding of the dependence of atherosclerosis candidate genes expression from miRNAs. These data allow us to consider miRNAs with target genes as perspective diagnostic and therapeutic molecular markers of atherosclerosis.

**Funding.** This study was supported by a grant (AP05132460) from the Ministry of Education and Science, Kazakhstan Republic, SRI of Biology and Biotechnology Problems, al-Farabi Kazakh National University.

Д.Д. Мукушкина<sup>1</sup>, З. Лабейт<sup>2</sup>, А.Т. Ивашенко<sup>1</sup>

<sup>1</sup>Биология және биотехнология мәселелерінің ғылыми-зерттеу институты,  
әл-Фараби атындағы Қазақ ұлттық университеті, Алматы, Қазақстан;

<sup>2</sup> Интегративті патофизиология институты, Гейдельберг университеті, Мангейм, Германия

## АТЕРОСКЛЕРОЗ КАНДИДАТТЫҚ ГЕННІҢ мРНҚ-МЕН миРНҚ-НЫҢ АССОЦИАЦИЯЛАРЫ

**Аннотация.** Атеросклероз – бұл көптеген генетикалық және экологиялық факторлар катысадын күрделі, мультифакторлы ауру болып табылады. Соңғы жылдарды атеросклероздың генетикалық қауін факторларын анықтауга деген қызығушылық ете тез өсуде. Атеросклероздың патогенезіне липидтердің алмасу ақаулары, эндотелиалды дисфункциясы, totify стрессі, қабыну және иммундық реакциялар, жасуша пролиферациясы және гемостатикалық ақаулар сияқты бірнеше факторлар қатысады. Тиңсінше, атеросклерозга кандидаттық

гендер анықталды, олар осы процестерге тікелей әсер етеді. Алайда, осы аурудың дамуына әсер ететін, әртүрлі биологиялық процестерге қатысатын гендерден басқа, miRNA (mRNA-inhibiting RNA) кандидаттық атеросклероз генинің экспрессиясын реттеу арқылы, атеросклероздың дамуына қатысатындығы анықталды. miRNA-тың гендерге әсерін зерттеу міндеттің қою кезінде, биоинформатикалық әдістерді қолдана отырып, miRNA пен максатты гендердің ең тиімді бірлестіктерін құруга болады. Бұл жұмыста miRNA-ның (mRNA-inhibiting RNA) атеросклероз үшін кандидаттық гендер mRNA-га өзара әрекеттесу сипаттамалары көлтірілген. miRNA-тың mRNA-га кандидаттық гендерімен байланыстыратын сайттар MirTarget бағдарламасын пайдаланып анықталды. Бұл бағдарлама mRNA -ның әртүрлі аймақтарында байланыстыратын сайттардың орналасуымен қатар, miRNA-ның mRNA-га байланысатын сайттардың басталуын, miRNA-ның mRNA-га еркін энергетикалық әсерлесу көрсеткішін ( $\Delta G_m$ , kJ/mole) және miRNA нуклеотидтерінің mRNA-ның байланыстыратын сайттарының ( $\Delta G/\Delta G_m$ ) толықтау дәрежесін анықтайды. Осы аймақтардағы miRNA -ның өзара әрекеттесу ерекшеліктерін анықтау үшін miRNA -ны байланыстыратын сайттарды іздеу 5'-трансляцияланбайтын аймақта (5'UTR), акуызды кодтау аймағында (CDS) және mRNA атеросклероздың кандидаттық гендерінің 3'-трансляцияланбайтын аймагында (3'UTR) жүргізілді. CDS аймагында әр түрлі miRNA-ның mRNA -мен өзара жеке әрекеттесу көбінесе 3'UTR және 5'UTR аймақтарына қарағанда, көбірек болатындығы анықталды. miRNA-мен атеросклерозының кандидатты гендері mRNA-ның әртүрлі аймақтарымен өзара әрекеттесуін зерттеу кезінде, жеке ассоциациялары mRNA-ның бір гана емес аймагында бар, гендер анықталды. Кандидат гендерінің miRNA-мен өзара әрекеттесуі екі бағытта болды: ABCA1; ABCG8; ADRB3; APH1B; ALOX15; HMOX1; ГА36; GNB3; ID3; PHACTR1; PROC; RTN3; SERPINE1; TIMP3 және ZNF202, және үш бағытта: ADCY9; LRP6; PDE4D және TNFSF12. Тиісінше, бұл гендерге көбінесе miRNA әсер етеді. Біздін зерттеуімізде таңдалған критерийлер негізінде, келесі кандидаттық гендер анықталды. Олар miRNA-мен еркін энергетикалық әрекеттесіп, -120 kJ/mole-га тең және келесі ассоциацияларда жогарырақ болады: 5'UTR-да - ID01336.3p-miR және ADCY9, ID02142.3p-miR және ALDH2, miR-4707-5p және APH1B, ID00216.3p-miR және CD40, miR-6789-5p және HIF1A, ID01242.3p-miR және LGALS2, ID02363.5p-miR және NOS3, ID00551.3p-miR және NPC1, ID01310.3p-miR және PDE4D, ID03397.3p-miR және PTGS2, ID00561.3p-miR және RTN4, ID01098.3p-miR және SERPINE1, ID02903.3p-miR және TIMP3, ID01323.3p-miR және TNFRSF11B, ID01770.3p-miR және ZNF202; в CDS - ID03064.3p-miR және ABCG8; ID02771.3p-miR және ADIPOR1; ID00252.5p-miR және ANGPTL2; ID00457.3p-miR және APOA1; ID01641.3p-miR және PDE4D; ID02050.3p-miR және TNF; ID01804.3p-miR және XBP1; ID00182.5p-miR және ZNF202; 3'UTR-да - ID00305.3p-miR және ADRB3; ID01213.5p-miR және AGTR2; ID02221.3p-miR және CDK5; ID03371.3p-miR және ID3; ID02229.3p-miR және LCN2; ID00704.5p-miR және TLR9. MiRNA мен кандидаттардың гендерінің ассоциациясы анықталды, олар 95% G/ $\Delta G_m$  мәнімен сипатталды, бұл miRNA нуклеотидтері мен байланыстыруышы жердің нуклеотидтерінің өзара әрекеттесуінің толықтай үйлесімділігін көрсетеді: 5'UTR - ID02813.3p-miR және CAPN10, ID01152.3p- miR және HMOX1, ID01840.5p-miR және PHACTR1; CDS - ID02129.5p-miR және CD4 бойынша; ID01797.3p-miR және PLA2G10; miR-1281 және PHACTR1; ID00182.5p-miR және ZNF202; 3'UTR - miR-1273g-3p және ALOX15. Анықталған қауымдастықтарды биомаркер ретінде атеросклероздың диагностикасында қолдануга болады.

**Тұйин сөздер:** атеросклероз, miRNA, mRNA, кандидаттық гендер, ассоциациялар.

Д.Д. Мукушкина<sup>1</sup>, З. Лабейт<sup>2</sup>, А.Т. Иващенко<sup>1</sup>

<sup>1</sup>НИИ проблем биологии и биотехнологии Казахского национального университета

им. аль-Фараби, Алматы, Казахстан;

<sup>2</sup>Институт Интегративной патофизиологии Университета Гейдельберга, Майнинген, Германия

## АССОЦИАЦИИ miRNA С mRNA КАНДИДАТНЫХ ГЕНОВ АТЕРОСКЛЕРОЗА

**Аннотация.** Атеросклероз представляет собой комплексное мультифакторное заболевание, в котором задействованы множественные генетические и экологические факторы. В последние годы очень быстро возрастает интерес к идентификации факторов генетического риска для атеросклероза. Множественные факторы, такие как дефекты в липидном метаболизме, эндотелиальная дисфункция, окислительный стресс, воспаление и иммунные ответы, клеточная пролиферация и гемостатические дефекты участвуют в патогенезе атеросклероза. Соответственно, выявились гены-кандидаты атеросклероза, которые непосредственно влияют на данные процессы. Однако помимо генов, вовлеченных в различные биологические процессы, которые влияют на развитие данного заболевания, было определено, что miRNA (mRNA-inhibiting RNA) также участвуют в развитии атеросклероза посредством регуляции экспрессии кандидатных генов атеросклероза. При постановке задачи изучения влияния miRNA на гены с помощью

биоинформационических методов можно установить наиболее эффективные ассоциации miRNA и геномишеней. В данной работе представлены характеристики взаимодействий miRNA с mRNA кандидатных генов атеросклероза. Сайты связывания miRNA с mRNA кандидатных генов определяли с помощью программы MirTarget. Данная программа, помимо расположения сайтов связывания в различных регионах mRNA, определяет начало сайтов связывания miRNA с mRNA, показатель свободной энергии взаимодействия miRNA с mRNA ( $\Delta G_m$ , kJ/mole), а также степень комплементарности нуклеотидов miRNA с сайтом связывания mRNA ( $\Delta G/\Delta G_m$ ). Поиск сайтов связывания miRNA проводили в 5'-нетранслируемой области (5'UTR), белок-кодирующей области (CDS) и 3'-нетранслируемой области (3'UTR) mRNA кандидатных генов атеросклероза с целью выявления особенностей взаимодействия miRNA в этих регионах. Выявлены 46, 59 и 33 геномишени, имеющие сайты связывания miRNA в 5'UTR, CDS и 3'UTR, соответственно. В CDS области установлено больше одиночных взаимодействий различных miRNA с mRNA в сравнении с областями 3'UTR и 5'UTR. В ходе изучения взаимодействий miRNA с различными областями mRNA кандидатных генов атеросклероза были выявлены гены, которые имели одиночные ассоциации не только в одной области mRNA. Гены-кандидаты имели взаимодействия с miRNA в двух областях: *ABCA1*; *ABCG8*; *ADRB3*; *APH1B*; *ALOX15*; *HMOX1*; *GAS6*; *GNB3*; *ID3*; *PHACTR1*; *PROC*; *RTN3*; *SERPINE1*; *TIMP3* и *ZNF202*, и в трех областях: *ADCY9*; *LRP6*; *PDE4D* и *TNFSF12*. Соответственно, данные гены наиболее подвержены влиянию со стороны miRNA. Основываясь на критериях, выбранных в нашем исследовании, были определены кандидатные гены, имеющие свободную энергию взаимодействия с miRNA равной 120 kJ/mole и выше в следующих ассоциациях: в 5'UTR - ID01336.3p-miR and *ADCY9*, ID02142.3p-miR and *ALDH2*, miR-4707-5p and *APH1B*, ID00216.3p-miR and *CD40*, miR-6789-5p and *HIF1A*, ID01242.3p-miR and *LGALS2*, ID02363.5p-miR and *NOS3*, ID00551.3p-miR and *NPC1*, ID01310.3p-miR and *PDE4D*, ID03397.3p-miR and *PTGS2*, ID00561.3p-miR and *RTN4*, ID01098.3p-miR and *SERPINE1*, ID02903.3p-miR and *TIMP3*, ID01323.3p-miR and *TNFRSF11B*, ID01770.3p-miR and *ZNF202*; в CDS - ID03064.3p-miR и *ABCG8*; ID02771.3p-miR и *ADIPO1*; ID00252.5p-miR и *ANGPTL2*; ID00457.3p-miR и *APOA1*; ID01641.3p-miR и *PDE4D*; ID02050.3p-miR и *TNF*; ID01804.3p-miR и *XBP1*; ID00182.5p-miR и *ZNF202*; в 3'UTR - ID00305.3p-miR и *ADRB3*; ID01213.5p-miR и *AGTR2*; ID02221.3p-miR и *CDK5*; ID03371.3p-miR и *ID3*; ID02229.3p-miR и *LCN2*; ID00704.5p-miR и *TLR9*. Выявлены ассоциации miRNA и кандидатных генов, которые характеризовались величиной  $\Delta G/\Delta G_m$ , равной 95%, что свидетельствует о почти полной комплементарности взаимодействия нуклеотидов miRNA и нуклеотидов сайта связывания: в 5'UTR - ID02813.3p-miR и *CAPN10*, ID01152.3p-miR и *HMOX1*, ID01840.5p-miR и *PHACTR1*; в CDS - ID02129.5p-miR и *CD4*; ID01797.3p-miR и *PLA2G10*; miR-1281 и *PHACTR1*; ID00182.5p-miR и *ZNF202*; в 3'UTR- miR-1273g-3p и *ALOX15*. Выявленные ассоциации можно использовать в качестве биомаркеров при диагностике атеросклероза.

**Ключевые слова:** атеросклероз, miRNA, mRNA, кандидатные гены, ассоциации.

#### Information about authors:

Mukushkina Dina Daurenbekovna – PhD-student, al-Farabi Kazakh National University, Almaty, Kazakhstan; e-mail: [dina.mukushkina@gmail.com](mailto:dina.mukushkina@gmail.com); <https://orcid.org/0000-0001-9506-3378>;

Siegfried Labeit – PhD, Professor, Institute for Integrative Pathophysiology of Heidelberg University, Mannheim, Germany; e-mail: [labeit@medma.de](mailto:labeit@medma.de); <https://orcid.org/0000-0002-9009-210X>;

Ivashchenko Anatoliy Timofeevich - doctor of biological sciences, professor, chief researcher, al-Farabi Kazakh National University, Scientific research institute of biology and biotechnology problems, Almaty, Kazakhstan; e-mail: [a\\_ivashchenko@mail.ru](mailto:a_ivashchenko@mail.ru); <https://orcid.org/0000-0002-7969-2016>

#### REFERENCES

- [1] Kislyak O.A., Malysheva N.V., Chirkova N.N. (2008) Risk factors for cardiovascular diseases in the development of diseases associated with atherosclerosis [Faktory riska serdechno-sosudistikh zabolеваний v razvitiy bolezney, svyazannykh s aterosklerozom] // Clinical Gerontology [Klinicheskaya Gerontologiya] 3:3-11 (in Russ.)
- [2] Anakwue R.C. (2014) Cardiovascular Disease Risk Profiling in Africa: Environmental Pollutants are not on the Agenda // Cardiovascular Toxicology, 14(3):193-207. DOI: 10.1007/s12012-013-9242-y.
- [3] Thum T., Mayr M. (2012) Review focus on the role of microRNA in cardiovascular biology and disease // Cardiovasc Res, 93:543–544. DOI: 10.1093/cvr/cvs085.
- [4] Fang Z., Du R., Edwards A., Flemington E.K., and Zhang K. (2013) The sequence structures of human microRNA molecules and their implications // PLoS One, 8:e54215. DOI: 10.1371/journal.pone.0054215.
- [5] Feinberg M.W. and Moore K.J. (2016) MicroRNA regulation of atherosclerosis // Circ. Res., 118:703–720. DOI: 10.1161/CIRCRESAHA.115.306300.
- [6] Kurozumi S., Yamaguchi Y., Kurosumi M., Ohira M., Matsumoto H., and Horiguchi J. (2017) Recent trends in microRNA research into breast cancer with particular focus on the associations between microRNAs and intrinsic subtypes // J. Hum. Genet., 62:15–24. DOI: 10.1038/jhg.2016.89.

- [7] Friedman R.C., Farh K.K., Burge C.B. and Bartel D.P. (2009) Most mammalian mRNAs are conserved targets of microRNAs // *Genome Res.*, 19:92–105. DOI: 10.1101/gr.082701.108.
- [8] Madrigal-Matute J., Rotllan N., Aranda J.F., and Fernandez-Hernando C. (2013) MicroRNAs and atherosclerosis // *Curr. Atheroscler. Rep.*, 15:322. DOI: 10.1007/s11883-013-0322-z.
- [9] Kucher A.N., Babushkina N.P. (2011). The role of microRNAs, genes of their biogenesis and functioning in the development of pathological conditions in humans Rol' mikroRNK, genov ikh biogeneza i funktsionirovaniya v razvitiu patologicheskikh sostoyaniy u cheloveka // *Medical Genetics [Meditinskaya Genetika]*, 1:3–13 (in Russ.)
- [10] Orom U.A., Nielsen F.C., and Lund A.H. (2008) MicroRNA-10a binds the 5'-UTR of ribosomal protein mRNAs and enhances their translation // *Mol. Cell*, 30:460–471. DOI: 10.1016/j.molcel.2008.05.001.
- [11] Andreou I., Sun X., Stone P.H., Edelman E.R. and Feinberg M.W. (2015) miRNAs in atherosclerotic plaque initiation, progression, and rupture // *Trends Mol. Med.*, 21:307–318. DOI: 10.1016/j.molmed.2015.02.003.
- [12] E. Lordin P. Loher A.G. Telonis K. Quann P. Clark, *et al* (2015) Analysis of 13 cell types reveals evidence for the expression of numerous novel primate- and tissue-specific microRNAs // *Proc. Natl. Acad. Sci. USA*, 112: E1106–1115. DOI: 10.1073/pnas.1420955112
- [13] Ivaschenko A.T., Pyrkova A.Y., Niyazova R.Y., Alybayeva A., Baskakov K. (2016) Prediction of miRNA binding sites in mRNA // *Bioinformation*, 12:237–240. DOI: 10.7717/peerj.8049
- [14] Karpova E., Gorbunova V., Stepanov N., Anisimova L., Korzhenevskaya M., Rosenfeld S., Togo E. (2018) Genetics in clinical practice [Genetika v klinicheskoy praktike] // SpecialLit, St. Petersburg. ISBN 978-5-299-00672-8
- [15] Zhang K., Zhang S., Zheng K., Hou Y., Liao L., He Y., Zhang L., Nebert D.W., Shi J., Su Z., Xiao C. (2004) Novel P143L polymorphism of the LCAT gene is associated with dyslipidemia in Chinese patients who have coronary atherosclerotic heart disease // *Biochem Biophys Res Commun*, 318: 4–10. DOI: 10.1016/j.bbrc.2004.03.177
- [16] Pocathikorn A., Granath B., Thiry E., Van Leuven F., Taylor R., Mamotte C. (2003) Influence of exonic polymorphisms in the gene for LDL receptor-related protein (LRP) on risk of coronary artery disease // *Atherosclerosis*, 168: 115–121. DOI: 10.1016/s0021-9150(03)00087-x
- [17] Yu X.H., Jiang N., Yao P.B., Zheng X.L., Cayabyab F.S., Tang C.K. (2014) NPC1, intracellular cholesterol trafficking and atherosclerosis // *Epub*, 429:69–75. DOI: 10.1016/j.cca.2013.11.026
- [18] Gudnason V., Kakko S., Nicaud V., Savolainen MJ., Kesäniemi YA., Tahvanainen E., Humphries S. (1999) Cholesteryl ester transfer protein gene effect on CETP activity and plasma high-density lipoprotein in European populations // *Eur J Clin Invest*, 29(2):116–128. DOI: 10.1046/j.1365-2362.1999.00412.x
- [19] Paradossi U., CioWni E., Clerico A., Botto N., Biagini A., Colombo M.G. (2004) Endothelial function and carotid intima-media thickness in young healthy subjects among endothelial nitric oxide synthase Glu298-Asp and T-786-C polymorphisms // *Stroke*, 35: 1305–1309. DOI: 10.1161/01.STR.0000126482.86708.37
- [20] Balistreri C.R., Candore G., Colonna-Romano G., Lio D., Caruso M., HoVmann E., Franceschi C., Caruso C. (2004) Role of Toll-like receptor 4 in acute myocardial infarction and longevity // *JAMA*, 292: 2339–2340. DOI: 10.1001/jama.292.19.2339
- [21] Ikeda S., Tanaka N., Arai T., Chida K., Muramatsu M., Sawabe M. (2012) Polymorphisms of LTA, LGALS2, and PSMA6 genes and coronary atherosclerosis: A pathological study of 1503 consecutive autopsy cases // *Atherosclerosis*, 221(2):458–60. DOI: 10.1016/j.atherosclerosis.2012.01.003